Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 568

1.

PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Lloret A, Beal MF.

Neurochem Res. 2019 May 7. doi: 10.1007/s11064-019-02809-1. [Epub ahead of print]

PMID:
31065944
2.

Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease.

Bose A, Beal MF.

Eur J Neurosci. 2019 Feb;49(4):525-532. doi: 10.1111/ejn.14264. Epub 2018 Dec 1. Review.

PMID:
30408242
3.

Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy.

Ranea-Robles P, Launay N, Ruiz M, Calingasan NY, Dumont M, Naudí A, Portero-Otín M, Pamplona R, Ferrer I, Beal MF, Fourcade S, Pujol A.

EMBO Mol Med. 2018 Aug;10(8). pii: e8604. doi: 10.15252/emmm.201708604.

4.

Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Tapias V, Jainuddin S, Ahuja M, Stack C, Elipenahli C, Vignisse J, Gerges M, Starkova N, Xu H, Starkov AA, Bettendorff L, Hushpulian DM, Smirnova NA, Gazaryan IG, Kaidery NA, Wakade S, Calingasan NY, Thomas B, Gibson GE, Dumont M, Beal MF.

Hum Mol Genet. 2018 Aug 15;27(16):2874-2892. doi: 10.1093/hmg/ddy201.

5.

Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations.

Chen Q, Kirk K, Shurubor YI, Zhao D, Arreguin AJ, Shahi I, Valsecchi F, Primiano G, Calder EL, Carelli V, Denton TT, Beal MF, Gross SS, Manfredi G, D'Aurelio M.

Cell Metab. 2018 May 1;27(5):1007-1025.e5. doi: 10.1016/j.cmet.2018.03.002. Epub 2018 Apr 12.

6.

Determination of Coenzyme A and Acetyl-Coenzyme A in Biological Samples Using HPLC with UV Detection.

Shurubor YI, D'Aurelio M, Clark-Matott J, Isakova EP, Deryabina YI, Beal MF, Cooper AJL, Krasnikov BF.

Molecules. 2017 Aug 23;22(9). pii: E1388. doi: 10.3390/molecules22091388.

7.

Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.

Chandra A, Sharma A, Calingasan NY, White JM, Shurubor Y, Yang XW, Beal MF, Johri A.

Hum Mol Genet. 2016 Jun 1;25(11):2269-2282. Epub 2016 Mar 22.

8.

Reductions in the mitochondrial enzyme α-ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental?

Chen H, Denton TT, Xu H, Calingasan N, Beal MF, Gibson GE.

J Neurochem. 2016 Dec;139(5):823-838. doi: 10.1111/jnc.13836.

9.

Mitochondrial dysfunction in Parkinson's disease.

Bose A, Beal MF.

J Neurochem. 2016 Oct;139 Suppl 1:216-231. doi: 10.1111/jnc.13731. Epub 2016 Aug 21. Review.

10.

Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.

Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, Thomas B.

J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.

11.

Simultaneous determination of tricarboxylic acid cycle metabolites by high-performance liquid chromatography with ultraviolet detection.

Shurubor YI, Cooper AJ, Isakova EP, Deryabina YI, Beal MF, Krasnikov BF.

Anal Biochem. 2016 Jun 15;503:8-10. doi: 10.1016/j.ab.2016.03.004. Epub 2016 Mar 19.

PMID:
27001310
12.

Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M.

Hum Mol Genet. 2016 Jan 15;25(2):317-27. doi: 10.1093/hmg/ddv477. Epub 2015 Nov 24.

13.

HPLC determination of α-ketoglutaramate [5-amino-2,5-dioxopentanoate] in biological samples.

Shurubor YI, Cooper AJ, Isakova EP, Deryabina YI, Beal MF, Krasnikov BF.

Anal Biochem. 2016 Feb 1;494:52-4. doi: 10.1016/j.ab.2015.11.003. Epub 2015 Nov 11.

PMID:
26576832
14.

Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain.

Clark-Matott J, Saleem A, Dai Y, Shurubor Y, Ma X, Safdar A, Beal MF, Tarnopolsky M, Simon DK.

Neurobiol Aging. 2015 Nov;36(11):2972-2983. doi: 10.1016/j.neurobiolaging.2015.07.020. Epub 2015 Jul 21.

15.

Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Morató L, Ruiz M, Boada J, Calingasan NY, Galino J, Guilera C, Jové M, Naudí A, Ferrer I, Pamplona R, Serrano M, Portero-Otín M, Beal MF, Fourcade S, Pujol A.

Cell Death Differ. 2015 Nov;22(11):1742-53. doi: 10.1038/cdd.2015.20. Epub 2015 Mar 27.

16.

Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Boussicault L, Hérard AS, Calingasan N, Petit F, Malgorn C, Merienne N, Jan C, Gaillard MC, Lerchundi R, Barros LF, Escartin C, Delzescaux T, Mariani J, Hantraye P, Beal MF, Brouillet E, Véga C, Bonvento G.

J Cereb Blood Flow Metab. 2014 Sep;34(9):1500-10. doi: 10.1038/jcbfm.2014.110. Epub 2014 Jun 18.

17.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
18.

Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study.

Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C.

Parkinsonism Relat Disord. 2014 May;20(5):545-8. doi: 10.1016/j.parkreldis.2014.02.003. Epub 2014 Feb 13.

PMID:
24593902
19.

Prospects for neuroprotective therapies in prodromal Huntington's disease.

Chandra A, Johri A, Beal MF.

Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Review.

20.

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M.

Hum Mol Genet. 2014 Jul 15;23(14):3716-32. doi: 10.1093/hmg/ddu080. Epub 2014 Feb 20.

Supplemental Content

Loading ...
Support Center